nach oben

Hepatology International

Erschienen in:

26.07.2016 | Review Article

New approaches for fibrosis regression in alcoholic cirrhosis

verfasst von: Wajahat Mehal, Uyen To

Erschienen in: Hepatology International | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Liver fibrosis is a dynamic process of fibrinogenesis and fibrinolysis. It is sequelae of recurrent injury and inflammation to the liver. Only recently has there been significant progress in understanding the pathophysiology behind liver fibrosis. This has allowed for the development of identifiable targets for potential therapies. In this article we will discuss the underlying general cellular mechanisms that play a key role in the pathway of fibrinogenesis and fibrinolysis and then focus on the mechanisms that are key in alcohol-induced liver fibrosis. Challenges in formulating potential fibrosis therapies as well as current potential targets for liver fibrosis will be reviewed as well.

Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Semin Liver Dis 2015;35(2):184–198

Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823

Wells RG. Portal fibroblasts in biliary fibrosis. Curr Pathobiol Rep 2014;2(4):185–190

Ramachandran P, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA 2012;109(46):E3186–E3195

Pellicoro A, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014;14(3):181–194

Pellicoro A, et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology 2012;55(6):1965–1975

Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014;60(5):1090–1096

Yata Y, et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002;35(5):1022–1030

Gilliam BL, DJ Riedel, Redfield RR. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 2011;9 Suppl 1:S9

10.

Zaldivar MM, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010;51(4):1345–1353

11.

Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 2011;29(4):140–152

12.

Wynn TA, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995;376(6541):594–596

13.

Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997;94(20):10663–10668

14.

Chiaramonte MG, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104(6):777–785

15.

Radaeva S, et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130(2):435–452

16.

Shah V, Haddad FG, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Investig 1997;100:2923–2930

17.

Herbst H, Frey A, Heinrichs O, et al. Heterogenity of liver cells expressing procollagen types I and IV in vivo. Histochem Cell Biol 1997;107:399–409

18.

Ding BS, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 2014;505(7481):97–102

19.

Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014;147(3):577–594.e1

20.

Tugues S, Fernandez-Varo G, Munoz-luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis and portal pressure in cirrhotic rats. Hepatology 2007;46:1919–1926

21.

Thabut D, et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011;54(2):573–585

22.

Kinnman N, et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003;83(2):163–173

23.

Nocito A, et al. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology 2007;45(2):369–376

24.

Pockros PJ, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007;45(3):569–578

25.

Myers JC, et al. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. Am J Pathol 1997;151(6):1729–1740

26.

Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990;10:1–10

27.

Lin SL, et al. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009;183(10):6733–6743

28.

Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 2013;1832(7):876–883

29.

Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 2006;63(19–20): 2304–2316

30.

Barry-Hamilton V, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16(9):1009–1017

31.

Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology 2015;61(3):1066–1079

32.

Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis 2015;35(2):146–156

33.

Wood MJ, Powell LW, Ramm GA. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 2008;111(9): 4456–4462

34.

Greenfield JR, et al. Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. J Clin Endocrinol Metab 2005;90(2):661–672

35.

Corrao G, et al. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998;33(4):381–392

36.

Day C. Who gets alcoholic liver disease: nature or nuture? (extended abstract). Acta Gastroenterol Belg 2003;66:290–229 (discussion 292–293)

37.

Zintzaras E, Stefenadis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006;43:352–361

38.

Marcos M, et al. Meta-analysis: glutathione-s-transferase allelic variants are associated with alcoholic liver disease. Aliment Pharmacol Ther 2011;34(10):1159–1172

39.

Nahon P, et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol 2005;3(3):292–298

40.

Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver 2014;8(3):237–241

41.

Chen P, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015;148(1):203–214.e16

42.

Zeng T, et al. Association between CD14-159C>T polymorphisms and the risk for alcoholic liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25(10):1183–1189

43.

Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010;3(3):178–1785

44.

Kwon HJ, et al. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 2014;60(1):146–157

45.

Mello T, et al. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008;29(1–2):17–21

46.

Nan YM, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis 2013;12:11

47.

Marcos M, et al. Common polymorphisms in interleukin genes (IL4, IL6, IL8 and IL12) are not associated with alcoholic liver disease or alcoholism in Spanish men. Cytokine 2009;45(3):158–161

48.

Roy N, et al. Genetic variants of TNFalpha, IL10, IL1beta, CTLA4 and TGFbeta1 modulate the indices of alcohol-induced liver injury in East Indian population. Gene 2012;509(1):178–188

49.

Wang Y, et al. Role of IRAK-M in alcohol induced liver injury. PLoS One 2013;8(2):e57085

50.

Kong X, et al. Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol 2013;28 Suppl 1:56–60

51.

Szabo G, et al. Gut-liver axis and sensing microbes. Dig Dis 2010;28(6):737–744

52.

Safety and efficacy of IMM 124-E for the treatment of severe alcoholic hepatitis (TREAT). https://clinicaltrials.gov/ct2/show/NCT01968382?term=anti-LPS&rank=1. Accessed 1 Mar 2016

53.

Chuncheon Sacred Heart Hospital. Effect of probiotics on gut-liver axis of alcoholic liver disease (EPALD). https://clinicaltrials.gov/ct2/show/NCT01501162. Accessed 1 Mar 2016

54.

H University. Randomised open-label multicenter study evaluating ciprofloxacin in severe alcoholic hepatitis. https://clinicaltrials.gov/ct2/show/NCT02326103. Accessed 1 Mar 2016

55.

L University Hospital. Efficacy of antibiotic therapy in severe alcoholic hepatitis treated with prednisolone (AntibioCor). https://clinicaltrials.gov/ct2/show/NCT02281929. Accessed 1 Mar 2016

56.

H.U.V.d.H.R Institute. Effects of rifaxicin in patients with acute alcoholic hepatitis (RIFA-AAH). https://clinicaltrials.gov/ct2/show/NCT02116556. Accessed 1 Mar 2016

57.

Korea Saint Vincent’s Hospital. Rifaxicin use in severe alcoholic hepatitis. https://clinicaltrials.gov/ct2/show/NCT02485106. Accessed 1 Mar 2016

58.

MM. Efficacy study of anakinra, pentoxyfilline, and zinc compared to methylprednisone in severe acute alcoholic hepatitis. https://clinicaltrials.gov/ct2/show/NCT01809132. Accessed 1 Mar 2016

59.

Nguyen-Khac E, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365(19):1781–1789

60.

Higuera-de la Tijera F, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol 2015;21(16):4975–4985

61.

PharmaKing. Efficacy and safety of MG in the patients with alcoholic fatty liver disease and alcoholic hepatitis. https://clinicaltrials.gov/ct2/show/NCT02019056. Accessed 1 Mar 2016

62.

B University. A novel pharmacotherapy for alcoholism and alcoholic liver disease. https://clinicaltrials.gov/ct2/show/NCT01504295. Accessed 1 Mar 2016

63.

Olinga P, Schuppan D. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol 2013;58(6):1252–1253

64.

Dawson DA, et al. Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction 2005;100(3):281–292

65.

Young S, Wood E, Ahamad K. Pharmacotherapy for alcohol addiction in a patient with alcoholic cirrhosis and massive upper gastrointestinal bleed: a case study. Drug Alcohol Rev 2016;35(2):236–239

Titel: New approaches for fibrosis regression in alcoholic cirrhosis
verfasst von: Wajahat Mehal
Uyen To
Publikationsdatum: 26.07.2016
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 5/2016
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-016-9752-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

New approaches for fibrosis regression in alcoholic cirrhosis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment

HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes

Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure

The role of bile salts in liver regeneration

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin